<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297697</url>
  </required_header>
  <id_info>
    <org_study_id>201706050</org_study_id>
    <nct_id>NCT03297697</nct_id>
  </id_info>
  <brief_title>Minimal Residual Disease in Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Invivoscribe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be
      performed in peripheral blood, the investigators wish to evaluate the ability of this assay
      to predict which patients are at higher risk of relapse from T-cell lymphoma. Additionally,
      as more is known about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to
      predict relapse, the investigators wish to explore the use of this technology in T-cell
      lymphomas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Lympotrack TCR clonality assay of evaluating minimal residual disease as measured by progression-free survival (PFS) at the completion of 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of Lympotrack TCR clonality assay of evaluating minimal residual disease as measured by the ability of Lymphotrack to detect minimal residual disease in at least 60% of baseline samples</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: Lymphotrack</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Patients will be treated with frontline chemotherapy per the treating physician's discretion. The intervention in this study will involve collection of the pre-treatment tumor biopsy to identify the tumor-specific clonotype and peripheral blood samples at various time points for assessment of minimal residual disease using the LymphoTrack MRD assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsy</intervention_name>
    <description>Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load</description>
    <arm_group_label>Arm 1: Lymphotrack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood draw</intervention_name>
    <description>-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse</description>
    <arm_group_label>Arm 1: Lymphotrack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lymphotrack TCR clonality assay</intervention_name>
    <description>-Assay with high sensitivity that can be performed with peripheral blood</description>
    <arm_group_label>Arm 1: Lymphotrack</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age.

          -  Histologically-confirmed peripheral T-cell lymphoma being treated with curative
             intent. Eligible histologies include: peripheral T-cell lymphoma, not otherwise
             specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphoma, ALK
             negative; and anaplastic large cell lymphoma, ALK positive.

          -  Plan for treatment with frontline multi-agent anthracycline containing chemotherapy
             for curative intent (for example, CHOP, CHOEP, EPOCH). A frontline therapy program can
             include different sequential phases of treatment, including high-dose therapy and
             autologous stem cell transplantation.

          -  Availability of pre-treatment test specimen from bone marrow, blood, lymph node, or
             alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy
             to identify the tumor-specific clonotype if tissue is not available at time of
             enrollment.

          -  Able to understand and willing to sign an IRB approved written informed consent
             document.

        Exclusion Criteria:

          -  Receiving second line of therapy or greater.

          -  Diagnosis of primary cutaneous T-cell lymphoma, extranodal NK-cell lymphoma, acute
             T-cell lymphoma/leukemia, hepatosplenic T-cell lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Mehta-Shah, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neha Mehta-Shah, M.D.</last_name>
    <phone>314-273-1070</phone>
    <email>mehta-n@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric D Jacobsen, M.D.</last_name>
      <phone>617-582-9086</phone>
      <email>eric_jacobsen@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Eric D Jacobsen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Mehta-Shah, M.D.</last_name>
      <phone>314-273-1070</phone>
      <email>mehta-n@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Neha Mehta-Shah, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy Bartlett, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Fehniger, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Cashen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brad Kahl, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Horwitz, M.D.</last_name>
      <phone>212-639-3045</phone>
    </contact>
    <investigator>
      <last_name>Steven Horwitz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

